MEF2D and cardiac hypertrophy: CRISPR-mediated endogenous activation of myocyte enhancer factor 2D (Mef2d) leads to cardiac hypertrophy in mice, indicating that CRISPR-mediated genome editing can be used to generate CVD mouse models by controlling transcription in the postnatal heart [163].